Instanosis Xylazine Rapid Test (Urine) Granted FDA Breakthrough Device Designation
Instanosis Inc. today announced that its Xylazine Rapid Test (Urine) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), representing a significant milestone in the development of rapid diagnostic tools addressing emerging drug threats.
